Obesity
Metabolic 4 original drugsMarket Leaders
Phase 3 Readouts Pro
12 active Phase 3 trials with confidence-graded completion dates.
Q2 2026
HDM1002 200mg, oral, once daily, 52 weeks
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Estimated · stale NCT06885021
Q3 2026
TQF3510 (Semaglutide Injection)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Estimated · stale NCT06738979
Unlock 9 more readouts with confidence-graded estimates
Upgrade to Pro Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Treatments by Mechanism
Top 9 mechanisms across 79 industry trials with a known mechanism of action.
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
30 trials 14 active 3 sponsors
GLP-1 Receptor Agonist
41 trials 4 active 3 sponsors
Interleukin-17A Antagonist
2 trials 1 active 1 sponsor
Cytochrome P450 3A4 Inducers [MoA]
1 trials 1 sponsor
Amide Local Anesthetic
1 trials 1 sponsor
Intestinal Lipase Inhibitor
1 trials 1 sponsor
Sodium-Glucose Cotransporter 2 Inhibitor
1 trials 1 sponsor
SGLT2
1 trials 1 sponsor
Nonsteroidal Anti-inflammatory Drug
1 trials 1 sponsor
MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.
Clinical Pipeline by Phase
721 industry-sponsored trials across 186 sponsors
Showing 24 of 24 trials
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-10 | NCT07438444 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-11 | NCT06864026 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2028-05 | NCT06857942 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2029-07 | NCT07247084 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2028-11-15 | NCT06571383 |
| Currax Pharmaceuticals | Naltrexone-Bupropion (NB) Combination | — | ACTIVE NOT RECRUITING | 2029-01 | NCT06098079 |
| WW International Inc | Bupropion-Naltrexone | — | COMPLETED | 2026-02-05 | NCT06605703 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2024-11-27 | NCT05579249 |
| Alvogen Korea | Qsymia 3.75Mg-23Mg Extended Release Capsule | — | COMPLETED | 2023-10-30 | NCT05378503 |
| VIVUS LLC | VI-0521 oral capsule | — | COMPLETED | 2021-04-16 | NCT03922945 |
| Novo Nordisk | Medication for chronic weight management (Rx) | — | COMPLETED | 2020-05-22 | NCT03799198 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | COMPLETED | 2020-01-29 | NCT04189848 |
| Eisai Inc. | Lorcaserin hydrochloride | — | COMPLETED | 2018-05-14 | NCT02019264 |
| Heilpflanzenwohl AG | Polyglucosamine Glucomannan normal dose (Verum) | — | COMPLETED | 2018-04-16 | NCT03557424 |
| Les Laboratoires des Médicaments Stériles | clopidogrel | — | COMPLETED | 2015-02 | NCT01509365 |
| VIVUS LLC | Qsymia | Cytochrome P450 3A4 Inducers [MoA] | COMPLETED | 2014-11 | NCT02229214 |
| Pacira Pharmaceuticals, Inc | EXPAREL | Amide Local Anesthetic [EPC] | COMPLETED | 2013-03 | NCT02142829 |
| InQpharm Group | — | — | COMPLETED | 2012-09 | NCT01505387 |
| InQpharm Group | — | — | COMPLETED | 2012-05 | NCT01435278 |
| InQpharm Group | — | — | COMPLETED | 2011-12 | NCT01407393 |
| AbbVie | Trospium Chloride, Extended Release (XR) | — | COMPLETED | 2011-12 | NCT00932022 |
| GSK | Orlistat | Intestinal Lipase Inhibitor [EPC] | COMPLETED | 2009-07 | NCT00752726 |
| Eisai Inc. | lorcaserin hydrochloride XR | — | TERMINATED | 2020-04-03 | NCT03338296 |
| Orexigen Therapeutics, Inc | Naltrexone HCl/Bupropion HCl ER | — | TERMINATED | 2016-06 | NCT02638129 |
Showing 100 of 175 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | RECRUITING | 2026-06-15 | NCT06893016 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 1 | — | RECRUITING | 2026-09-20 | NCT07279194 |
| Vanda Pharmaceuticals | Tradipitant | — | RECRUITING | 2026-12-01 | NCT07446439 |
| Eli Lilly | Orforglipron | — | RECRUITING | 2027-02 | NCT06672549 |
| Eli Lilly | Orforglipron | — | RECRUITING | 2027-02 | NCT06672939 |
| Hudson Biotech | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-02-14 | NCT07481747 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | RECRUITING | 2027-05-07 | NCT06931028 |
| Gan & Lee Pharmaceuticals. | GZR18 | — | RECRUITING | 2027-06-30 | NCT07150975 |
| Eli Lilly | Orforglipron | — | RECRUITING | 2027-09 | NCT06948435 |
| Eli Lilly | Retatrutide | — | RECRUITING | 2027-09 | NCT07035093 |
| Gan & Lee Pharmaceuticals. | GZR18 injection | — | RECRUITING | 2027-09 | NCT07292441 |
| Metsera, a wholly owned subsidiary of Pfizer | MET097 | — | RECRUITING | 2027-09-21 | NCT07311850 |
| Amgen | Maridebart cafraglutide | — | RECRUITING | 2027-09-29 | NCT07225686 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | RECRUITING | 2027-10 | NCT06439277 |
| Pfizer | PF-08653944 | — | RECRUITING | 2027-10-12 | NCT07400653 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | RECRUITING | 2027-10-31 | NCT07255209 |
| Hangzhou Sciwind Biosciences Co., Ltd. | XW003 injection | — | RECRUITING | 2027-12-16 | NCT07387094 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-01 | NCT07282600 |
| Kailera | KAI-9531 | — | RECRUITING | 2028-02-28 | NCT07284875 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-03 | NCT07321886 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-03 | NCT07353931 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-03 | NCT07369011 |
| Kailera | KAI-9531 | — | RECRUITING | 2028-03-20 | NCT07284979 |
| Eli Lilly | Mirikizumab | — | RECRUITING | 2028-04 | NCT06937086 |
| Eli Lilly | Mirikizumab | — | RECRUITING | 2028-05 | NCT06937099 |
| Eli Lilly | Eloralintide | — | RECRUITING | 2028-06 | NCT07392190 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-06-06 | NCT07503210 |
| Hangzhou Sciwind Biosciences Co., Ltd. | XW003 injection | — | RECRUITING | 2028-06-19 | NCT07434050 |
| Amgen | Maridebart Cafraglutide | — | RECRUITING | 2028-06-30 | NCT07037433 |
| Amgen | Maridebart cafraglutide | — | RECRUITING | 2028-06-30 | NCT07037459 |
| Roche | — | — | RECRUITING | 2028-07-24 | NCT07351045 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-07 | NCT07533175 |
| Roche | — | — | RECRUITING | 2028-08-07 | NCT07351058 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-14 | NCT07481630 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-08-14 | NCT07509307 |
| Eli Lilly | Retatrutide | — | RECRUITING | 2028-10 | NCT07357415 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2029-06-26 | NCT07339423 |
| Novo Nordisk | Cagrilintide | — | RECRUITING | 2030-03-20 | NCT07253285 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 injection | — | RECRUITING | 2026-01-27 | NCT06839664 |
| BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. | 5 mg BGM0504 injection | — | RECRUITING | 2025-11-27 | NCT06704581 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-11 | NCT06914895 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-11 | NCT06962280 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2026-11 | NCT06649045 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-12 | NCT06662383 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | ACTIVE NOT RECRUITING | 2026-12-31 | NCT06884293 |
| Amgen | Maridebart Cafraglutide | — | ACTIVE NOT RECRUITING | 2027-01-21 | NCT06858839 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 injection | — | ACTIVE NOT RECRUITING | 2027-03 | NCT07285902 |
| Novo Nordisk | CagriSema (Cagrilintide B and Semaglutide I) | — | ACTIVE NOT RECRUITING | 2027-03-01 | NCT07011667 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2027-05-11 | NCT07220642 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2027-05-12 | NCT07220759 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2027-07 | NCT07232719 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2027-08 | NCT06993792 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2027-08 | NCT06972459 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2027-08 | NCT06972472 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2027-10 | NCT05556512 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2028-04 | NCT06859268 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2028-08-28 | NCT06780449 |
| Boehringer Ingelheim | — | — | ACTIVE NOT RECRUITING | 2026-05-01 | NCT06077864 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-05 | NCT05929079 |
| Gan & Lee Pharmaceuticals. | GZR18 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06728124 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-05 | NCT06075667 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 Tablets | — | ACTIVE NOT RECRUITING | 2026-05 | NCT06904105 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-04 | NCT05882045 |
| Eli Lilly | Retatrutide | — | ACTIVE NOT RECRUITING | 2026-04 | NCT05929066 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | ACTIVE NOT RECRUITING | 2026-01-08 | NCT06588283 |
| Hanmi Pharmaceutical Company Limited | HM11260C | — | ACTIVE NOT RECRUITING | 2025-12-31 | NCT06174779 |
| Rhythm Pharmaceuticals, Inc. | Setmelanotide | — | ACTIVE NOT RECRUITING | 2025-12-22 | NCT05093634 |
| Vincentage Pharma Co., Ltd | VCT220 | — | ACTIVE NOT RECRUITING | 2025-11-25 | NCT06939296 |
| Novo Nordisk | Semaglutide | GLP-1 Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2025-10-15 | NCT05726227 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | ACTIVE NOT RECRUITING | 2025-09-17 | NCT06184568 |
| Eli Lilly | Orforglipron | — | ACTIVE NOT RECRUITING | 2025-07-25 | NCT05869903 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | ACTIVE NOT RECRUITING | 2025-06-27 | NCT06164873 |
| Novo Nordisk | Cagrilintide | — | ACTIVE NOT RECRUITING | 2024-10-30 | NCT05567796 |
| Novo Nordisk | Liraglutide | GLP-1 Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2023-08-01 | NCT04775082 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 200mg, oral, once daily, 52 weeks | — | NOT YET RECRUITING | 2026-05-30 | NCT06885021 |
| Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Semaglutide | GLP-1 Receptor Agonist [EPC] | NOT YET RECRUITING | 2026-05-30 | NCT06633783 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | TQF3510 (Semaglutide Injection) | — | NOT YET RECRUITING | 2026-07 | NCT06738979 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | NOT YET RECRUITING | 2026-08-01 | NCT07469800 |
| HK inno.N Corporation | IN-B00009 | — | NOT YET RECRUITING | 2026-12-31 | NCT07192263 |
| Beijing QL Biopharmaceutical Co.,Ltd | Zovaglutide dose 1 | — | NOT YET RECRUITING | 2027-05-29 | NCT07230119 |
| MindRank AI Ltd | MDR-001 | — | NOT YET RECRUITING | 2027-06 | NCT07274137 |
| Novo Nordisk | Cagrisema | — | NOT YET RECRUITING | 2027-11-29 | NCT07357766 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 | — | NOT YET RECRUITING | 2027-12 | NCT07528027 |
| Amgen | Maridebart Cafraglutide | — | NOT YET RECRUITING | 2028-01-03 | NCT07575399 |
| Novo Nordisk | Cagrisema | — | NOT YET RECRUITING | 2028-02-23 | NCT07564414 |
| Pfizer | PF-08653944 | — | NOT YET RECRUITING | 2028-05-04 | NCT07595549 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2028-06-26 | NCT07571109 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2028-07-12 | NCT07571005 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2028-12-12 | NCT07400107 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2029-07-23 | NCT07567001 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2026-04-22 | NCT06388187 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2026-03-16 | NCT05803421 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2026-01-20 | NCT06047548 |
| Boehringer Ingelheim | — | — | COMPLETED | 2025-12-12 | NCT06066528 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-12-08 | NCT06131437 |
| Boehringer Ingelheim | Survodutide | — | COMPLETED | 2025-12-03 | NCT06176365 |
| Boehringer Ingelheim | — | — | COMPLETED | 2025-12-02 | NCT06066515 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2025-11-21 | NCT06584916 |
| Eli Lilly | Ixekizumab | Interleukin-17A Antagonist [EPC] | COMPLETED | 2025-11-18 | NCT06588296 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2025-11-14 | NCT05931367 |
Showing 100 of 205 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Hangzhou Sciwind Biosciences Co., Ltd. | ecnoglutide tablets | — | RECRUITING | 2026-08-03 | NCT07243171 |
| AstraZeneca | AZD6234 | — | RECRUITING | 2026-08-06 | NCT07017179 |
| Innovent Biologics (Suzhou) Co. Ltd. | IBI362 | — | RECRUITING | 2026-09-24 | NCT06862908 |
| Arrowhead Pharmaceuticals | ARO-ALK7 | — | RECRUITING | 2026-10 | NCT06937203 |
| KeyBioscience AG | KBP-336 | — | RECRUITING | 2026-11 | NCT06833749 |
| Regeneron | Olatorepatide | — | RECRUITING | 2026-11-23 | NCT07431086 |
| Novo Nordisk | UBT251 | — | RECRUITING | 2027-01-14 | NCT07395687 |
| AstraZeneca | AZD9550 | — | RECRUITING | 2027-01-29 | NCT06151964 |
| NeuroBiogen Co., Ltd | KDS2010 | — | RECRUITING | 2027-01-31 | NCT07009171 |
| AB Biotics, SA | — | — | RECRUITING | 2027-02-01 | NCT07193927 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 dose level 1 | — | RECRUITING | 2027-02-04 | NCT07521631 |
| Hudson Biotech | MOTS-c (MDP) | — | RECRUITING | 2027-02-14 | NCT07505745 |
| Ikaria Bioscience Pty Ltd | RN3161 | — | RECRUITING | 2027-02-15 | NCT07245771 |
| Eli Lilly | Macupatide | — | RECRUITING | 2027-03 | NCT07215559 |
| Actimed Therapeutics Ltd | (S)-pindolol benzoate | — | RECRUITING | 2027-03 | NCT07101939 |
| Hudson Biotech | Retatrutide (LY3437943) | — | RECRUITING | 2027-03-14 | NCT07467447 |
| Alnylam Pharmaceuticals | ALN-2232 | — | RECRUITING | 2027-04-27 | NCT07463846 |
| Kailera | KAI-9531 | — | RECRUITING | 2027-05 | NCT07458269 |
| Kailera | KAI-7535 | — | RECRUITING | 2027-07-07 | NCT07497880 |
| Alnylam Pharmaceuticals | ALN-4324 | — | RECRUITING | 2027-08-31 | NCT06845202 |
| Eli Lilly | LY3305677 | — | RECRUITING | 2027-09 | NCT06143956 |
| Arrowhead Pharmaceuticals | ARO-INHBE | — | RECRUITING | 2027-09-17 | NCT06700538 |
| Amgen | Maridebart cafraglutide | — | RECRUITING | 2027-09-29 | NCT07441252 |
| Veru Inc. | Enobosarm | — | RECRUITING | 2027-10 | NCT07446998 |
| Lallemand Health Solutions | — | — | RECRUITING | 2028-02 | NCT06786052 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 | — | RECRUITING | 2030-07-11 | NCT07134335 |
| Tonghua Dongbao Pharmaceutical Co.,Ltd | THDBH120 injection | — | RECRUITING | 2026-02-13 | NCT07036601 |
| Mankind Pharma Limited | MKP10241 | — | RECRUITING | 2026-01-19 | NCT07098663 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 | — | RECRUITING | 2026-01-11 | NCT06911203 |
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | RECRUITING | 2025-12-20 | NCT06254261 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 injection or placebo | — | RECRUITING | 2025-09-23 | NCT06886126 |
| MindRank AI Ltd | MDR-001 | — | RECRUITING | 2025-07-15 | NCT06778850 |
| Golo | — | — | RECRUITING | 2024-11 | NCT05844644 |
| AstraZeneca | AZD6234 | — | ACTIVE NOT RECRUITING | 2026-05-27 | NCT06851858 |
| Eli Lilly | LY3841136 | — | ACTIVE NOT RECRUITING | 2026-06 | NCT06603571 |
| Carmot Therapeutics, Inc. | Enicepatide | — | ACTIVE NOT RECRUITING | 2026-06-01 | NCT06628362 |
| Verdiva Bio Dev Limited | VRB-101 | — | ACTIVE NOT RECRUITING | 2026-07 | NCT07281937 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | aleniglipron or placebo | — | ACTIVE NOT RECRUITING | 2026-08 | NCT07169942 |
| Zealand Pharma | Petrelintide | — | ACTIVE NOT RECRUITING | 2026-08-13 | NCT06926842 |
| NodThera Limited | NT-0796 | — | ACTIVE NOT RECRUITING | 2026-08-21 | NCT07220629 |
| Roche | RO7204239 | — | ACTIVE NOT RECRUITING | 2026-08-24 | NCT06965413 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-09 | NCT05536804 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Aleniglipron | — | ACTIVE NOT RECRUITING | 2026-09 | NCT07400588 |
| Biohaven Therapeutics Ltd. | Taldefgrobep Alfa | — | ACTIVE NOT RECRUITING | 2026-09 | NCT07281495 |
| Innovent Biologics (Suzhou) Co. Ltd. | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-09-30 | NCT07000955 |
| Rhythm Pharmaceuticals, Inc. | Setmelanotide | — | ACTIVE NOT RECRUITING | 2026-10-31 | NCT06772597 |
| Skye Bioscience, Inc. | Nimacimab injection | — | ACTIVE NOT RECRUITING | 2026-11-20 | NCT06577090 |
| Beijing QL Biopharmaceutical Co.,Ltd | ZT006 | — | ACTIVE NOT RECRUITING | 2026-12-12 | NCT07230132 |
| Novo Nordisk | NNC0662-0419 | — | ACTIVE NOT RECRUITING | 2026-12-14 | NCT07184632 |
| Hanmi Pharmaceutical Company Limited | HM15275 | — | ACTIVE NOT RECRUITING | 2027-01 | NCT07205900 |
| Hangzhou Sciwind Biosciences Co., Ltd. | XW003 injection | — | ACTIVE NOT RECRUITING | 2027-02-27 | NCT07073417 |
| AstraZeneca | AZD9550 | — | ACTIVE NOT RECRUITING | 2026-05-25 | NCT06862791 |
| Regeneron | Trevogrumab-Part A | — | ACTIVE NOT RECRUITING | 2026-05-18 | NCT06299098 |
| Roche | RO7795081 | — | ACTIVE NOT RECRUITING | 2026-04-28 | NCT07081958 |
| Metsera, a wholly owned subsidiary of Pfizer | MET233 | — | ACTIVE NOT RECRUITING | 2026-04-15 | NCT07022977 |
| Eli Lilly | Bimagrumab | — | ACTIVE NOT RECRUITING | 2026-04 | NCT06643728 |
| Corxel Pharmaceuticals | CX11 | — | ACTIVE NOT RECRUITING | 2026-03-23 | NCT07011797 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-01-08 | NCT06037252 |
| Metsera, a wholly owned subsidiary of Pfizer | MET097 | — | ACTIVE NOT RECRUITING | 2025-12-16 | NCT06973720 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | DA-302168S | — | ACTIVE NOT RECRUITING | 2025-12 | NCT06953063 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Aleniglipron | — | ACTIVE NOT RECRUITING | 2025-10-24 | NCT06693843 |
| Regor Pharmaceuticals Inc. | RGT001-075 | — | ACTIVE NOT RECRUITING | 2025-09-19 | NCT06867718 |
| Metsera, a wholly owned subsidiary of Pfizer | MET097 | — | ACTIVE NOT RECRUITING | 2025-07-03 | NCT06712836 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 Tablet | — | ACTIVE NOT RECRUITING | 2025-05-30 | NCT06621316 |
| Palatin Technologies, Inc | bremelanotide | — | ACTIVE NOT RECRUITING | 2025-02-05 | NCT06565611 |
| Verdiva Bio Dev Limited | VRB-101 | — | NOT YET RECRUITING | 2026-11-30 | NCT07553299 |
| ERX Pharmaceuticals | ERX1000 | — | NOT YET RECRUITING | 2027-05 | NCT07570758 |
| Biophytis | BIO101 | — | NOT YET RECRUITING | 2027-06 | NCT07411378 |
| S1 Biopharma, Inc. | S1B-509 low dose | — | NOT YET RECRUITING | 2027-06-15 | NCT06517797 |
| Pfizer | PF-08653945 | — | NOT YET RECRUITING | 2027-08-04 | NCT07575932 |
| Biomed Industries, Inc. | NA-931 | — | NOT YET RECRUITING | 2027-08-15 | NCT06732245 |
| Eli Lilly | Macupatide | — | NOT YET RECRUITING | 2027-09 | NCT07589608 |
| Sirius Therapeutics Co., Ltd. | SRSD384 injection | — | NOT YET RECRUITING | 2027-10 | NCT07557355 |
| Roche | Petrelintide | — | NOT YET RECRUITING | 2027-11-12 | NCT07589686 |
| ARKAY Therapeutics | Metformin | — | NOT YET RECRUITING | 2028-11-26 | NCT03686657 |
| Gan and Lee Pharmaceuticals, USA | GZR18 | — | NOT YET RECRUITING | 2026-02-09 | NCT06737042 |
| MindRank AI Ltd | MDR-001 | — | NOT YET RECRUITING | 2025-07-30 | NCT06606483 |
| Empros Pharma AB | EMP16-02 120 mg orlistat/40 mg acarbose | — | NOT YET RECRUITING | 2025-07-29 | NCT06993428 |
| Leeuwenhoek Laboratories Co. Ltd. | — | — | NOT YET RECRUITING | 2024-12-01 | NCT06578143 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 100 mg QD | — | NOT YET RECRUITING | 2024-10-30 | NCT06500299 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | aleniglipron or placebo | — | COMPLETED | 2026-01-12 | NCT06703021 |
| Eli Lilly | LY3549492 | — | COMPLETED | 2026-01-07 | NCT06683508 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | COMPLETED | 2025-12-15 | NCT06373146 |
| Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd. | CPX101 or placebo 120mg Q2W | — | COMPLETED | 2025-12-15 | NCT06532578 |
| Carmot Therapeutics, Inc. | Enicepatide | — | COMPLETED | 2025-12-08 | NCT06525935 |
| AstraZeneca | AZD5004 | — | COMPLETED | 2025-11-21 | NCT06579092 |
| Pfizer | PF-07976016 | — | COMPLETED | 2025-10-23 | NCT06717425 |
| The United Bio-Technology (Hengqin) Co., Ltd. | UBT251 Injection 2.0 mg and UBT251 Injection Placebo | — | COMPLETED | 2025-10-22 | NCT07177469 |
| Vanda Pharmaceuticals | Tradipitant | — | COMPLETED | 2025-10-06 | NCT06804603 |
| Eli Lilly | Retatrutide | — | COMPLETED | 2025-10-01 | NCT05936151 |
| Zealand Pharma | Petrelintide | — | COMPLETED | 2025-09-30 | NCT06662539 |
| Novo Nordisk | Cagrilintide | — | COMPLETED | 2025-09-24 | NCT06131372 |
| Zomagen Biosciences Ltd. | VTX3232 Dose A | — | COMPLETED | 2025-09-10 | NCT06771115 |
| Terns, Inc. | TERN-601 | — | COMPLETED | 2025-08-19 | NCT06854952 |
| AstraZeneca | AZD6234 | — | COMPLETED | 2025-08-08 | NCT06595238 |
| Carmot Therapeutics, Inc. | CT-868 | — | COMPLETED | 2025-07-09 | NCT06062069 |
| Eli Lilly | LY3841136 | — | COMPLETED | 2025-05-30 | NCT06230523 |
| Beijing QL Biopharmaceutical Co.,Ltd | ZT002 Injection | — | COMPLETED | 2025-05-07 | NCT07020884 |
| Veru Inc. | Enobosarm | — | COMPLETED | 2025-04-11 | NCT06282458 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2025-04-10 | NCT06326060 |
Showing 100 of 317 trials (top 100 by completion date — export for full list)
| Sponsor | Asset | MoA | Status | Primary Completion | NCT |
|---|---|---|---|---|---|
| Innovent Biologics Technology Limited (Shanghai R&D Center) | IBI3032 tablets | — | RECRUITING | 2026-05-29 | NCT07160400 |
| Novo Nordisk | Liraglutide | GLP-1 Receptor Agonist [EPC] | RECRUITING | 2026-06-19 | NCT07225816 |
| Vincentage Pharma Co., Ltd | CX11 (VCT220) | — | RECRUITING | 2026-06-30 | NCT07349381 |
| Eli Lilly | LY4086940 | — | RECRUITING | 2026-07 | NCT06945419 |
| Eli Lilly | LY3549492 | — | RECRUITING | 2026-07 | NCT07232732 |
| Gan & Lee Pharmaceuticals. | GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets | — | RECRUITING | 2026-07-05 | NCT07128888 |
| Gan & Lee Pharmaceuticals. | GZR18 injection | — | RECRUITING | 2026-07-12 | NCT07144098 |
| CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | SYH9017 | — | RECRUITING | 2026-08-01 | NCT06830343 |
| Shanghai World Leader Pharmaceutical Co., Ltd. | Semaglutide Nasal Spray | — | RECRUITING | 2026-08-21 | NCT07465965 |
| Eli Lilly | LY3971297 | — | RECRUITING | 2026-09 | NCT06148272 |
| Laekna Limited | LAE102 intravenous administration | — | RECRUITING | 2026-09-30 | NCT06493084 |
| AbbVie | ABBV-295 | — | RECRUITING | 2026-10 | NCT07291232 |
| Syntis Bio | SYNT101 | — | RECRUITING | 2026-10 | NCT07307274 |
| Wave Life Sciences Ltd. | WVE-007 | — | RECRUITING | 2026-10 | NCT06842186 |
| Amgen | COC | — | RECRUITING | 2026-10-07 | NCT07523711 |
| MBX Biosciences | MBX 4291 | — | RECRUITING | 2026-10-30 | NCT07142707 |
| Eli Lilly | LY4064912 | — | RECRUITING | 2026-11 | NCT07152002 |
| Boehringer Ingelheim | BI 456906 | — | RECRUITING | 2026-11-04 | NCT05202353 |
| NeuroBo Pharmaceuticals Inc. | DA-1726 | — | RECRUITING | 2026-11-09 | NCT06252220 |
| Eli Lilly | LY4167586 | — | RECRUITING | 2026-12 | NCT07225556 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | SHR-2906 Injection | — | RECRUITING | 2026-12 | NCT07280936 |
| RANI Therapeutics | PG-102 | — | RECRUITING | 2026-12-01 | NCT06891287 |
| Beijing QL Biopharmaceutical Co.,Ltd | Zovaglutide | — | RECRUITING | 2026-12-03 | NCT07443059 |
| Roche | RO7795081 | — | RECRUITING | 2026-12-04 | NCT06982131 |
| Roche | RO7795081 | — | RECRUITING | 2026-12-29 | NCT07499050 |
| Novo Nordisk | NNC6989-0001 A | — | RECRUITING | 2027-01-21 | NCT07437079 |
| Novo Nordisk | Glucose-dependent Insulinotropic Polypeptide (GIP) | — | RECRUITING | 2027-01-26 | NCT07411560 |
| Boehringer Ingelheim | — | — | RECRUITING | 2027-01-26 | NCT07407348 |
| Pfizer | PF-08653944 | — | RECRUITING | 2027-01-27 | NCT07508241 |
| Eli Lilly | Brenipatide | — | RECRUITING | 2027-02 | NCT07476118 |
| Hanmi Pharmaceutical Company Limited | HM17321 | — | RECRUITING | 2027-03 | NCT07219589 |
| AstraZeneca | AZD1043 | — | RECRUITING | 2027-03-15 | NCT07511205 |
| Alveus Therapeutics, Inc. | ALV-100 | — | RECRUITING | 2027-04 | NCT07399678 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-5817 Injection | — | RECRUITING | 2027-04 | NCT06934408 |
| Novo Nordisk | NNC0662-0419 | — | RECRUITING | 2027-04-08 | NCT07525791 |
| Novo Nordisk | Cagrilintide | — | RECRUITING | 2027-04-13 | NCT07557953 |
| Suzhou Alphamab Co., Ltd. | KN069 | — | RECRUITING | 2027-04-30 | NCT06547775 |
| Novo Nordisk | INV-347 | — | RECRUITING | 2027-09-15 | NCT07153172 |
| Novo Nordisk | CagriSema (Cagrilintide B + semaglutide I) | — | RECRUITING | 2027-10-12 | NCT07184086 |
| Novo Nordisk | NNC0487-0111 | — | RECRUITING | 2028-01-19 | NCT07508020 |
| Laekna Limited | LAE103 injection | — | RECRUITING | 2028-03-20 | NCT07230496 |
| Novo Nordisk | Cagrilintide | — | RECRUITING | 2028-04-28 | NCT07527195 |
| Novo Nordisk | Cagrilintide | — | RECRUITING | 2028-05-03 | NCT07010432 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM1812 | — | RECRUITING | 2026-05-15 | NCT07224399 |
| Shanghai Xitaili Biomedicine Technology co., Ltd. | XTL6001 | — | RECRUITING | 2026-04 | NCT07205432 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 tablets | — | RECRUITING | 2026-03-31 | NCT07239973 |
| Novo Nordisk | NNC0174-1213 A | — | RECRUITING | 2026-03-26 | NCT06719011 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM1812 | — | RECRUITING | 2026-03-02 | NCT07294235 |
| Shanghai Minwei Biotechnology Co., Ltd | MWN109 tablet | — | RECRUITING | 2026-03 | NCT06938269 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 Injection multi-dose pen | — | RECRUITING | 2026-02-12 | NCT07382908 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | HS-20094 AI pen; | — | RECRUITING | 2026-02-04 | NCT07057674 |
| OrsoBio, Inc | TLC-6740 Oral Solution | — | RECRUITING | 2026-02 | NCT05822544 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-9531 Tablet | — | RECRUITING | 2026-02 | NCT07150962 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Metformin | — | RECRUITING | 2026-01-12 | NCT07331389 |
| BrightGene Bio-Medical Technology Co., Ltd. | BGM0504 | — | RECRUITING | 2026-01-12 | NCT07166081 |
| Gan & Lee Pharmaceuticals. | GZR18 injection | — | RECRUITING | 2025-10-09 | NCT07141030 |
| Shanghai Minwei Biotechnology Co., Ltd | Subcutaneous single and mutiple dose | — | RECRUITING | 2025-09-25 | NCT06859853 |
| Boehringer Ingelheim | — | — | ACTIVE NOT RECRUITING | 2026-05-28 | NCT07413913 |
| Amgen | Maridebart Cafraglutide | — | ACTIVE NOT RECRUITING | 2026-05-28 | NCT07226778 |
| Amgen | Maridebart Cafraglutide | — | ACTIVE NOT RECRUITING | 2026-06-26 | NCT07313761 |
| Eli Lilly | LY3537031 | — | ACTIVE NOT RECRUITING | 2026-07 | NCT06606106 |
| Amgen | Maridebart Cafraglutide | — | ACTIVE NOT RECRUITING | 2026-08-26 | NCT07229157 |
| Roche | RO7204239 | — | ACTIVE NOT RECRUITING | 2026-09-13 | NCT07137585 |
| Pfizer | PF-08653944 | — | ACTIVE NOT RECRUITING | 2026-09-18 | NCT07400679 |
| Novo Nordisk | NNC0638-0355 | — | ACTIVE NOT RECRUITING | 2026-09-24 | NCT06577766 |
| Eli Lilly | Tirzepatide | Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC] | ACTIVE NOT RECRUITING | 2026-11 | NCT07299084 |
| Boehringer Ingelheim | Survodutide | — | ACTIVE NOT RECRUITING | 2027-01-08 | NCT06745284 |
| Biomea Fusion Inc. | BMF-650 | — | ACTIVE NOT RECRUITING | 2026-05 | NCT07223216 |
| Guangdong Raynovent Biotech Co., Ltd | RAY1225 | — | ACTIVE NOT RECRUITING | 2025-12-27 | NCT07362030 |
| Innovent Biologics Technology Limited (Shanghai R&D Center) | IBI3032 | — | ACTIVE NOT RECRUITING | 2025-12-24 | NCT07170319 |
| Metabolics Pharma | ENT-03 | — | ACTIVE NOT RECRUITING | 2024-08-12 | NCT05925920 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 | — | NOT YET RECRUITING | 2026-06-12 | NCT07559240 |
| Vivani Medical, Inc | Semaglutide (Wegovy) weekly injection | — | NOT YET RECRUITING | 2026-08 | NCT07430059 |
| Suzhou Siran Biotechnology Co.,Ltd. | Dose escalation of SA030 | — | NOT YET RECRUITING | 2026-08-18 | NCT07479862 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | SYH2082 Injection | — | NOT YET RECRUITING | 2026-10-28 | NCT07532655 |
| Suzhou Sanegene Bio Inc. | SGB-7342 | — | NOT YET RECRUITING | 2026-10-28 | NCT07324850 |
| Novo Nordisk | NNC0113-5840 | — | NOT YET RECRUITING | 2026-11-26 | NCT07566390 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Acetaminophen | Nonsteroidal Anti-inflammatory Drug [EPC] | NOT YET RECRUITING | 2026-12-01 | NCT07502001 |
| Beijing QL Biopharmaceutical Co.,Ltd | ZT002 injection, metformin, warfarin | — | NOT YET RECRUITING | 2026-12-05 | NCT07550816 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531 injection；Placebo | — | NOT YET RECRUITING | 2027-01 | NCT07559136 |
| Regeneron | REGN20934 | — | NOT YET RECRUITING | 2027-02-22 | NCT07594093 |
| iBio, Inc. | IBIO-600 | — | NOT YET RECRUITING | 2027-05 | NCT07487376 |
| Novo Nordisk | Cagrilintide D | — | NOT YET RECRUITING | 2027-05-28 | NCT07597018 |
| Shenzhen Kangzhe Biotechnology Co., Ltd. | CMS-D008 | — | NOT YET RECRUITING | 2027-11-24 | NCT07518589 |
| Novo Nordisk | NNC0487-0111 | — | NOT YET RECRUITING | 2027-12-01 | NCT07587710 |
| Novo Nordisk | NNC0497-0040 | — | NOT YET RECRUITING | 2028-02-18 | NCT07578584 |
| Daewoong Pharmaceutical Co. LTD. | DWRX5003 | — | NOT YET RECRUITING | 2026-04-30 | NCT07539415 |
| Huons Co., Ltd. | HUC2-676 | — | NOT YET RECRUITING | 2026-03-24 | NCT07337174 |
| MindRank AI Ltd | MDR-001 | — | NOT YET RECRUITING | 2025-09-15 | NCT07110766 |
| Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Repaglinide | — | NOT YET RECRUITING | 2025-02 | NCT06601517 |
| Hangzhou Sciwind Biosciences Co., Ltd. | XW003 injection | — | COMPLETED | 2026-04-18 | NCT07143227 |
| Zealand Pharma | Petrelintide | — | COMPLETED | 2026-03-31 | NCT07338214 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | HRS-4729 injection | — | COMPLETED | 2026-03-12 | NCT06762600 |
| Shandong Suncadia Medicine Co., Ltd. | HRS-7535 Tablets | — | COMPLETED | 2026-03-08 | NCT07269756 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2026-01-28 | NCT07004322 |
| Eli Lilly | Orforglipron | — | COMPLETED | 2026-01-26 | NCT06824051 |
| Kailera | KAI-7535 | — | COMPLETED | 2026-01-26 | NCT07294898 |
| Eli Lilly | Eloralintide and Tirzepatide | — | COMPLETED | 2026-01-19 | NCT06916065 |
| Vincentage Pharma Co., Ltd | VCT220 | — | COMPLETED | 2026-01-18 | NCT07347808 |
| Novo Nordisk | NNC0519-0130 | — | COMPLETED | 2026-01-12 | NCT06718998 |
Novel Drugs by Company (New molecular entities)
Reformulations (6 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Drug Targets
Generic Drugs (5 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs